Ellipsis Biotherapeutics

Ellipsis Biotherapeutics is a Cambridge-based biotechnology company focused on discovering and developing small molecule therapeutics that target RNA biology. Backed by Atlas Venture, the company utilizes a proprietary platform that integrates structural biology, computational chemistry, and high-throughput screening to identify novel compounds capable of modulating RNA function and stability. Their research primarily targets oncology, rare genetic diseases, and neurological disorders, aiming to address targets that have been historically considered "undruggable" by conventional protein-focused approaches. The company operates in an early-stage/stealth mode, building a pipeline of programs that leverage the therapeutic potential of the human transcriptome.